Judge Strikes Down Trump's $100K H-1B Visa Fee
A federal judge struck down Trump's $100,000 H-1B visa fee as an unlawful tax, a win for hospitals that rely on foreign-trained physicians.
Takeaways from the most recent news in the technology and policies shaping healthcare.
AstraZeneca's oral GLP-1 drug showed promise in mid-stage obesity and diabetes trials, but its standing against rival pills remains unclear.
Domain-specific AI trained on real clinical operations data is helping sponsors design smarter, more feasible trial protocols and avoid costly amendments.
Sophia Genetics and Memorial Sloan Kettering signed an MOU to form a joint venture building an AI-powered precision oncology hub in New York City.
Telehealth and digital tools are expanding access to pediatric behavioral healthcare, but integration into primary care and proven outcomes remain the key tests.
A federal judge struck down Trump's $100,000 H-1B visa fee as an unlawful tax, a win for hospitals that rely on foreign-trained physicians.
Klinic raised $24 million to expand its enablement platform for behavioral health and specialty providers.
Vida Health partnered with Instacart to provide members grocery stipends for healthy foods as part of its cardiometabolic care programs.
Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.
HHS affordability czar Casey Mulligan says distorted incentives like provider taxes, not coverage gaps, are the root of high US healthcare costs.
GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.
Oura and Whoop are working to move wearable health data into clinical workflows, a shift that could reshape how physicians use continuous patient data.
Trump affordability czar Casey Mulligan told hospital finance leaders that Medicaid cuts will boost affordability, as executives prepare to absorb the fallout.
Newsletter
One email. The funding, policy, and AI stories that actually matter, in plain English. No spam, unsubscribe anytime.